Atherogenics, Inc.
Records under this name other than patents Atherogenics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,121,319 | Monoesters of probucol for the treatment of cardiovascular and inflammatory disease Formerly held Term ended Term ended May 14, 2018 · From the USPTO record | Term ended | Term ended May 14, 2018 | From the USPTO record |
| US 6,147,250 | Compounds and methods for the inhibition of the expression of VCAM-1 Formerly held Term ended Term ended May 14, 2018 · From the USPTO record | Term ended | Term ended May 14, 2018 | From the USPTO record |
| US 8,252,840 | Methods of derivatives of probucol for the treatment of type II diabetes Formerly held Lapsed on the fee record Ended Aug 28, 2016 · From the USPTO record | Lapsed on the fee record | Ended Aug 28, 2016 | From the USPTO record |
| US 7,294,737 | Process of preparing esters and ethers of probucol and derivatives thereof Formerly held Lapsed on the fee record Ended Nov 13, 2015 · From the USPTO record | Lapsed on the fee record | Ended Nov 13, 2015 | From the USPTO record |
| US 7,273,948 | Process of preparing esters and ethers of probucol and derivatives thereof Formerly held Lapsed on the fee record Ended Sep 25, 2015 · From the USPTO record | Lapsed on the fee record | Ended Sep 25, 2015 | From the USPTO record |
| US 7,271,274 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease Formerly held Lapsed on the fee record Ended Sep 18, 2015 · From the USPTO record | Lapsed on the fee record | Ended Sep 18, 2015 | From the USPTO record |
| US 6,617,352 | Compounds and methods for the inhibition of the expression of VCAM-1 Formerly held Lapsed on the fee record Ended Sep 9, 2015 · From the USPTO record | Lapsed on the fee record | Ended Sep 9, 2015 | From the USPTO record |
| US 6,602,914 | Compounds and methods for the inhibition of the expression of VCAM-1 Formerly held Lapsed on the fee record Ended Aug 5, 2015 · From the USPTO record | Lapsed on the fee record | Ended Aug 5, 2015 | From the USPTO record |
| US 7,247,714 | Protection against oxidative stress and inflammation by a cytoprotective response element Formerly held Lapsed on the fee record Ended Jul 24, 2015 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2015 | From the USPTO record |
| US 6,548,699 | Compounds and methods for the inhibition of the expression of VCAM-1 Formerly held Lapsed on the fee record Ended Apr 15, 2015 · From the USPTO record | Lapsed on the fee record | Ended Apr 15, 2015 | From the USPTO record |